# US 2025/0145662 A1 · Methods for reducing lipase activity using stress

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145662 A1
- Document ID: US20250145662A1
- Status: Published application
- Kind: A1
- Application number: 18/934,626
- Filed: 2024-11-01
- Published: 2025-05-08
- Earliest claimed: 2023-11-02
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Xiaolin Tang; Leonid Breydo
- Web page: https://patentgrep.com/patent/US20250145662A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- C07K 1/18: Ion-exchange chromatography
- C07K 1/36: by a combination of two or more processes of different types
- C07K 16/065: {Purification, fragmentation}
- C07K 16/247: {IL-4}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4Rα) are provided. The formulations may contain, in addition to an anti-IL-4Rα antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant. Methods for producing pharmaceutical formulations with reduced lipase activity are also provided, which may include subjecting a drug substance to agitation stress, heat stress, and additional ion exchange or size exclusion chromatography. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.

## Claims

### Claim 1

A method for producing a pharmaceutical composition with reduced lipase activity, comprising:
(a) subjecting a sample including a protein of interest and a lipase to stress conditions to form a sample with inactivated lipase;
(b) subjecting said sample with inactivated lipase to a purification step to form a high molecular weight (HMW)-depleted sample; and
(c) formulating said HMW-depleted sample with at least one fatty acid ester to produce a pharmaceutical composition with reduced lipase activity,
wherein said pharmaceutical composition has reduced lipase activity compared to a pharmaceutical composition formulated from a sample that was not subjected to stress conditions, and wherein said reduced lipase activity is measured after a period of storage at long-term storage conditions or accelerated storage conditions of at least 2 weeks.

### Claim 2 (depends on 1)

The method of claim 1, wherein said protein of interest is an antibody, an antibody-derived protein, an antibody fragment, a monoclonal antibody, a bispecific antibody, a fusion protein, an antibody-drug conjugate, or a therapeutic protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein said protein of interest is Dupilumab.

### Claim 4 (depends on 2)

The method of claim 2, wherein said stress conditions include agitation stress and/or heat stress.

### Claim 5 (depends on 4)

The method of claim 4, wherein said agitation stress comprises shaking said sample at from 50 to 500 rpm, from 200 to 300 rpm, about 50 rpm, about 75 rpm, about 100 rpm, about 125 rpm, about 150 rpm, about 200 rpm, about 225 rpm, about 250 rpm, about 275 rpm, about 300 rpm, about 325 rpm, about 350 rpm, about 375 rpm, about 400 rpm, about 425 rpm, about 450 rpm, about 475 rpm, or about 500 rpm.

### Claim 6 (depends on 5)

The method of claim 5, wherein said agitation stress comprises shaking said sample for from 1 to 96 hours, from 24 to 48 hours, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 60 hours, about 72 hours, about 84 hours, or about 96 hours.

### Claim 7 (depends on 4)

The method of claim 4, wherein said heat stress comprises storing said sample at from about 25° C. to about 60° C., from about 30° C. to about 60° C., from about 35° C. to about 55° C., from about 40° C. to about 50° C., from about 44° C. to about 46° C., about 25° C., about 30° C., about 35° C., about 40° C., about 45° C., about 50° C., about 55° C., or about 60° C.

### Claim 8 (depends on 7)

The method of claim 7, wherein said heat stress comprises storing said sample at said temperature from 1 day to 6 months, from 3 days to 3 months, from 1 week to 2 months, from 0.5 months to 1 month, about 1 day, about 2 days, about 3 days, about 1 week, about 2 weeks, about 0.5 months, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 3.5 months, about 4 months, about 4.5 months, about 5 months, about 5.5 months, or about 6 months.

### Claim 9 (depends on 4)

The method of claim 4, wherein said purification step comprises filtration, enrichment, or chromatographic separation.

### Claim 10 (depends on 9)

The method of claim 9, wherein said chromatographic separation comprises cation exchange chromatography.

### Claim 11 (depends on 9)

The method of claim 9, wherein said chromatographic separation comprises size exclusion chromatography.

### Claim 12 (depends on 9)

The method of claim 9, wherein said HMW-depleted sample comprises less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% HMW species.

### Claim 13 (depends on 9)

The method of claim 9, wherein said formulating step further comprises adding excipients to said HMW-depleted sample.

### Claim 14 (depends on 9)

The method of claim 9, wherein said fatty acid ester is polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.

### Claim 15 (depends on 9)

The method of claim 9, wherein said period of storage is from about 2 weeks to about 5 years, from about 2 weeks to about 3 years, from about 2 weeks to about 1 year, from about 2 weeks to about 6 months, from about 1 month to about 5 years, from about 1 month to about 3 years, from about 1 month to about 1 year, from about 1 month to about 6 months, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months, about 18 months, about 2 years, about 3 years, about 4 years, or about 5 years.

### Claim 16 (depends on 4)

The method of claim 4, wherein said long-term storage conditions comprise storage at a temperature from about 0° C. to about 10° C., about 0° C., about 5° C., or about 10° C.

### Claim 17 (depends on 4)

The method of claim 4, wherein said accelerated storage conditions comprise storage at a temperature from about 35° C. to about 60° C., from about 45° C. to about 55° C., about 35° C., about 40° C., about 45° C., about 50° C., about 55° C., or about 60° C.

### Claim 18 (depends on 4)

The method of claim 4, wherein a measure of reduced lipase activity comprises a quantification of fatty acid ester degradation.

### Claim 19 (depends on 18)

The method of claim 18, wherein said quantification comprises an enzymatic colorimetric assay for non-esterified fatty acids, mass spectrometry, charged aerosol detection, and/or liquid chromatography.

### Claim 20 (depends on 18)

The method of claim 18, wherein said quantification comprises determining a percent of fatty acid ester recovered from said pharmaceutical composition with reduced lipase activity after said period of storage using charged aerosol detection-liquid chromatography.

### Claim 21 (depends on 20)

The method of claim 20, wherein said percent is above 80%, above 85%, above 90%, above 95%, above 99%, about 85%, about 90%, about 95%, about 99%, or about 100%.

### Claim 22 (depends on 4)

The method of claim 4, wherein a measure of reduced lipase activity comprises a quantification of particles per unit volume.

### Claim 23 (depends on 22)

The method of claim 22, wherein said particles comprise visible particles and/or subvisible particles.

### Claim 24 (depends on 22)

The method of claim 22, wherein said particles comprise particles≥10 μm in diameter and/or particles≥25 um in diameter.

### Claim 25 (depends on 22)

The method of claim 22, wherein said particles comprise fatty acid particles.

### Claim 26 (depends on 22)

The method of claim 22, wherein said quantification comprises light obscuration, optical microscopy, micro-flow image analysis, flow cytometry, Coulter counting, and/or submicron particle tracking.

### Claim 27 (depends on 22)

The method of claim 22, wherein a number of particles per mL in said pharmaceutical composition with reduced lipase activity is below 500, below 200, below 100, below 50, below 10, or below 5.

### Claim 28 (depends on 4)

The method of claim 4, wherein said recombinant host cell is selected from a group consisting of a CHO cell, a CHO-K1 cell, and variations thereof.

### Claim 29 (depends on 27)

The method of claim 27, wherein said lipase is a host cell protein.

### Claim 30 (depends on 29)

The method of claim 29, wherein said lipase has an increased susceptibility to inactivation in stress conditions compared to said protein of interest.

### Claim 31 (depends on 4)

A protein formulation comprising a protein and at least one fatty acid ester made by the method of claim 4.
